ArticleMolecular biology reports2026
SREBF1 expression is associated with lipid metabolism-related signatures, and transient SREBF1 silencing is accompanied by increased apoptosis in pancreatic cancer cells.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy characterized by extensive metabolic adaptation. Sterol regulatory element-binding transcription factor 1 (SREBF1) encodes sterol regulatory element-binding protein 1 (SREBP1), a transcriptional regulator of lipogenic genes. This study investigated the association between SREBF1 expression and lipid metabolism-related transcriptional features in PDAC and assessed cellular responses to transient SREBF1 silencing. METHODS AND
resultsSREBF1 expression was evaluated using RNA-sequencing data from TCGA-PAAD and GTEx and paired microarray data from GSE62452 and GSE183795. The analysis included 179 TCGA-PAAD tumors and 171 TCGA/GTEx non-tumor pancreatic samples, together with 61 matched tumor-adjacent pairs from GSE62452 and 102 matched pairs from GSE183795. TCGA-PAAD tumors were stratified at the median SREBF1 expression level for differential-expression analysis, GSEA, and GSVA. SREBF1 expression was higher in the TCGA/GTEx tumor-versus-normal comparison (P < 0.0001), with concordant increases in GSE62452 (P < 0.05) and GSE183795 (P < 0.01). SREBF1-high tumors exhibited lipid metabolism-related transcriptional features, including higher fatty-acid-metabolism and cholesterol-homeostasis pathway scores. In BxPC-3 and SW1990 cells, transient SREBF1 silencing with one selected siRNA was accompanied by decreased precursor SREBP1 (~ 122 kDa) and FASN protein levels, qualitatively reduced clonogenic outgrowth, and an increased Annexin V-positive apoptotic fraction.
conclusionSREBF1 expression is associated with lipid metabolism-related transcriptional features in PDAC. Transient SREBF1 silencing was accompanied by reduced FASN protein levels, qualitatively reduced clonogenic outgrowth, and increased apoptosis. These findings identify SREBP1-associated lipid metabolism as a candidate vulnerability that requires further validation but do not establish a direct SREBP1-FASN-cell-survival mechanism or therapeutic efficacy.
Indexed as
Identifiers
42862406What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.